These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 11762559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
    Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ.
    J Clin Pharmacol; 1998 Jul; 38(7):593-602. PubMed ID: 9702843
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
    Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397
    [Abstract] [Full Text] [Related]

  • 4. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.
    Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F.
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2714-8. PubMed ID: 9420044
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
    Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Bradley JS, Kimko HC, Kearns GL, Shalayda K, Curtin C, Maldonado SD, Blumer JL.
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2668-73. PubMed ID: 17517842
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis.
    Conway SP, Etherington C, Peckham DG, Brownlee KG, Whitehead A, Cunliffe H.
    J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430
    [Abstract] [Full Text] [Related]

  • 9. Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox®.
    Berben P, Stappaerts J, Vink MJA, Domínguez-Vega E, Somsen GW, Brouwers J, Augustijns P.
    Eur J Pharm Biopharm; 2018 Nov; 132():231-236. PubMed ID: 29959034
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.
    Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3151-3. PubMed ID: 15273137
    [Abstract] [Full Text] [Related]

  • 11. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules.
    Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG.
    Mycoses; 1999 Aug; 42(11-12):591-600. PubMed ID: 10680434
    [Abstract] [Full Text] [Related]

  • 12. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
    Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E, Dad L, Piscitelli SC, Walsh TJ.
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
    Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K.
    Clin Infect Dis; 2001 Oct 15; 33(8):e83-90. PubMed ID: 11550120
    [Abstract] [Full Text] [Related]

  • 17. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.
    de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, De Beule K.
    Antimicrob Agents Chemother; 1998 Feb 15; 42(2):404-8. PubMed ID: 9527794
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution.
    Miyake K, Irie T, Arima H, Hirayama F, Uekama K, Hirano M, Okamaoto Y.
    Int J Pharm; 1999 Mar 15; 179(2):237-45. PubMed ID: 10053216
    [Abstract] [Full Text] [Related]

  • 20. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
    Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L.
    Antimicrob Agents Chemother; 1998 Jul 15; 42(7):1862-5. PubMed ID: 9661037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.